Although the results obtained so far are not encouraging, the PI3K/Akt/mTOR axis still retains a great interest as a possible target for therapeutic intervention in GBM, and novel compounds are continuously developed and tested to overcome the limitations observed with the Rapamycin derivatives (rapalogs). The gene discussed is AKT1; the disease is glioblastoma.